We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Kratší doba podání ocrelizumabu při léčbě roztroušené sklerózy.
- Authors
Peterka, Marek; Potužník, Pavel
- Abstract
Patients with multiple sclerosis can nowadays be treated with the humanized monoclonal antibody ocrelizumab. This drug has so far been administered parenterally intravenously at an interval of 3,5 hours. As we know from other fields of medicine, reducing the infusion time can minimise the burden of treatment on patients and reduce the length of stay in the infusion room without compromising patient safety, which is especially important in the light of the current COVID-19 pandemic. The ENSEMBLE PLUS study investigated the safety of ocrelizumab administration when the infusion time was reduced to 2 hours. This article reports the results of this study.
- Publication
Neurologie Pro Praxi, 2021, Vol 22, Issue 4, p300
- ISSN
1213-1814
- Publication type
Article